Luseogliflozin Persistently Lowers Glycemia and Body Weight Over a Period of Two Years in Patients With Type 2 Diabetes
The effects of luseogliflozin on glucose and BW reduction were sustained for at least two years, indicating similarity to other SGLT2 inhibitors.
Authors
- Koh Yamashita (ORCID: https://orcid.org/0000-0002-2228-7407)
- Jun-ichirou Mori (ORCID: https://orcid.org/0009-0008-5568-0804)
- Toru Aizawa (ORCID: https://orcid.org/0009-0004-9179-4885)
Institutions
- Shinshu University (JP)
- Shinshu University Hospital (JP)
- Aizawa Hospital (JP)
Publication Details
- Journal
- Cureus
- Published
- 2025-02-04
- DOI
- https://doi.org/10.7759/cureus.78503
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00